Related Experiment Video
Updated: Aug 29, 2025

High-Throughput Transcriptome Analysis for Investigating Host-Pathogen Interactions
Published on: March 5, 2022
Deciphering COVID-19 host transcriptomic complexity and variations for therapeutic discovery against new variants
Jing Xing1, Rama Shankar1, Meehyun Ko2
1Department of Pediatrics and Human Development, Michigan State University, Grand Rapids, MI 49503, USA.
Abstract:
The molecular manifestations of host cells responding to SARS-CoV-2 and its evolving variants of infection are vastly different across the studied models and conditions, imposing challenges for host-based antiviral drug discovery. Based on the postulation that antiviral drugs tend to reverse the global host gene expression induced by viral infection, we retrospectively evaluated hundreds of signatures derived from 1,700 published host transcriptomic profiles of SARS/MERS/SARS-CoV-2 infection using an iterative data-driven approach. A few of these signatures could be reversed by known anti-SARS-CoV-2 inhibitors, suggesting the potential of extrapolating the biology for new variant research. We discovered IMD-0354 as a promising candidate to reverse the signatures globally with nanomolar IC50 against SARS-CoV-2 and its five variants. IMD-0354 stimulated type I interferon antiviral response, inhibited viral entry, and down-regulated hijacked proteins. This study demonstrates that the conserved coronavirus signatures and the transcriptomic reversal approach that leverages polypharmacological effects could guide new variant therapeutic discovery.
Insights
Researchers identified a drug, IMD-0354, that reverses host gene expression changes caused by SARS-CoV-2 infection and its variants. This approach aids in discovering new antiviral therapies for evolving coronaviruses.
Area of Science:
- Virology
- Genomics
- Pharmacology
Background:
- Host cell responses to SARS-CoV-2 and its variants vary significantly, complicating host-based antiviral drug discovery.
- Antiviral drugs are hypothesized to counteract viral infection by reversing global host gene expression patterns.
Purpose of the Study:
- To identify host transcriptomic signatures of coronavirus infection and evaluate their potential for therapeutic discovery.
- To discover novel antiviral compounds effective against SARS-CoV-2 and its variants using a transcriptomic reversal approach.
Main Methods:
- Retrospective analysis of 1,700 host transcriptomic profiles from SARS, MERS, and SARS-CoV-2 infections.
- Iterative, data-driven evaluation of gene expression signatures to identify those reversible by antiviral agents.
- In vitro testing of candidate compounds, including IMD-0354, against SARS-CoV-2 and its variants.
Main Results:
- Identified conserved coronavirus infection signatures across different host models and conditions.
- Discovered IMD-0354, a compound that globally reverses host gene expression signatures with nanomolar IC50 values against SARS-CoV-2 and five variants.
- IMD-0354 demonstrated antiviral activity by stimulating type I interferon response, inhibiting viral entry, and reducing viral protein hijacking.
Conclusions:
- The transcriptomic reversal approach, leveraging conserved coronavirus signatures and polypharmacology, is a viable strategy for discovering new antiviral therapeutics.
- IMD-0354 shows significant promise as a broad-spectrum antiviral agent against SARS-CoV-2 and its evolving variants.
Related Concept Videos
Leaky Scanning
Viruses with RNA Genomes
Single Nucleotide Polymorphisms-SNPs
Viral Mutations
Ribosome Profiling
Applications of ribosome profiling
Ribosome profiling has many applications, including in vivo monitoring of translation inside a particular organ or tissue type and quantifying new protein synthesis levels.
The technique...

